Mentice AB (publ) (FRA:MN2)

Germany flag Germany · Delayed Price · Currency is EUR
1.125
+0.005 (0.45%)
Last updated: Jun 26, 2026, 8:08 AM CET
Market Cap33.00M -32.1%
Revenue (ttm)26.15M -4.1%
Net Income-1.94M
EPS-0.07
Shares Out n/a
PE Ration/a
Forward PE455.22
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open1.125
Previous Close1.120
Day's Range1.125 - 1.125
52-Week Range0.800 - 1.420
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 23, 2026

About Mentice AB

Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as t... [Read more]

Industry Prepackaged Software
Founded 1998
Employees 119
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol MN2

Financial Performance

In 2025, Mentice AB's revenue was 279.09 million, a decrease of -3.87% compared to the previous year's 290.33 million. Losses were -32.33 million, 75.5% more than in 2024.

Financial numbers in SEK Financial Statements

News

Mentice AB Earnings Call Transcript: Q1 2026

Q1 delivered 26% organic revenue growth and a 50% increase in order intake, with strong momentum across MedTech and healthcare systems segments. EBITDA improved but remained negative due to seasonality, while cost discipline and a robust pipeline support a positive outlook.

7 weeks ago - Transcripts

Mentice AB Quarterly report: Q1 2026

Mentice AB has published its Q1 2026 quarterly earnings report on May 7, 2026.

7 weeks ago - Filings

Mentice AB (OSTO:MNTC) Q1 2026 Earnings Report Preview: What to Expect

Mentice AB (OSTO:MNTC) Q1 2026 Earnings Report Preview: What to Expect

7 weeks ago - GuruFocus

Mentice AB Transcript: DNB Carnegie Healthcare Seminar 2026

The presentation highlighted strong growth in simulation solutions for minimally invasive procedures, with a broadened customer base and robust financial performance. Strategic investments in advanced training and digital twin technology aim to drive further expansion and profitability.

3 months ago - Transcripts

Mentice AB Earnings Call Transcript: Q4 2025

Q4 saw strong organic growth in sales and order intake, with EBITDA margin rising to 25%. The Americas and MDI segment led performance, while cost control and R&D focus position the company for continued growth in 2026.

4 months ago - Transcripts

Mentice AB Quarterly report: Q4 2025

Mentice AB has published its Q4 2025 quarterly earnings report on February 26, 2026.

4 months ago - Filings

Mentice AB Annual report: Q4 2025

Mentice AB has published its Q4 2025 annual report on February 26, 2026.

4 months ago - Filings

Mentice AB Earnings Call Transcript: Q3 2025

Q3 saw 22% year-over-year net sales growth, driven by the medical device industry in Americas and EMEA, with improved EBITDA margin from cost reductions. A successful rights issue and the launch of a portable simulation system support future growth, while hospital and APAC segments face challenges.

8 months ago - Transcripts

Mentice AB Quarterly report: Q3 2025

Mentice AB has published its Q3 2025 quarterly earnings report on November 6, 2025.

8 months ago - Filings

Mentice AB Earnings Call Transcript: Q2 2025

Q2 net sales declined 33% year-over-year due to a strong prior-year comparison and cautious market, but cost-saving measures and new product clearances position the business for improved profitability and growth in the second half. Rights issue to raise SEK 32 million is well supported.

1 year ago - Transcripts

Mentice AB Quarterly report: Q2 2025

Mentice AB has published its Q2 2025 quarterly earnings report on July 24, 2025.

1 year ago - Filings